Cardiometabolic Consequences of Targeted Anticancer Therapies

Avirup Guha, Yan Gong, David Deremer, Jocelyn Owusu-Guha, Susan F. Dent, Richard K. Cheng, Neal Lee Weintraub, Neeraj Agarwal, Michael G. Fradley

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Cardiometabolic disease (CMD) is the most common preventable cause of death in the world. A number of components are included in the spectrum of CMD, such as metabolic syndrome/obesity, hyperglycemia/diabetes, dyslipidemia, and hypertension, which are independently associated with cardiovascular disease risk. These conditions often occur together, and patients with cancer frequently undergo treatments that can generate or worsen CMD. This review highlights and presents mechanistic and epidemiological evidence regarding CMD in 4 categories of anticancer medications, namely, mTOR/PI3K-Akt inhibitors, multitargeted tyrosine kinase inhibitor, immune checkpoint inhibitor therapy, and endocrine therapy. Patients taking these medications need careful monitoring during therapy. There is a role for cardio-oncology and onco-primary care specialists in optimally managing patients at risk to mitigate CMD during treatment with these and other investigational anticancer medications.

Original languageEnglish (US)
Pages (from-to)515-521
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Issue number4
StatePublished - Oct 2021


  • anticancer therapy
  • cardio-oncology
  • cardiometabolic disease
  • diabetes
  • hypertension

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Cardiometabolic Consequences of Targeted Anticancer Therapies'. Together they form a unique fingerprint.

Cite this